Solithromycin as A Potential Novel Antibiotic Against Neisseria Gonorrhoeae Resistance
Keywords:
antibiotic, CEM-101, gonorrhea, solithromycin, resistance
Abstract
Gonorrhea is one of the most often sexually transmitted infection in the world. In 2016, WHO stated the Southeast Asia region as the fourth-highest incidence rate and prevalence of gonorrhea. One of the current problems with gonorrhea is related to its emerging resistance to first-line drugs such as cephalosporins, macrolides, and fluoroquinolones. This resistance has an impact on the difficulty of finding effective antibiotics to eradicate the infection, thus risking financial loss and infertility in sexually active age patients. This literature review will discuss solithromycin, the first fluoroketolide in phase III clinical trial, and show its potential as a new antibiotic against infection with resistant Neisseria gonorrhoeae. Literatures are searched using Pubmed and Google Scholar search engines with keywords: antibiotics, CEM-101, clinical trial, Neisseria gonorrhoeae, new treatment, pharmacology, pharmacokinetics, resistance, safety, and solithromycin. This semisynthetic antibiotic is supported by a different chemical structure from previous macrolides; improving solithromycin becomes more stable and able to bind easier with bacterial ribosomes. Pharmacologically, solithromycin provides an advantage in its high bioavailability, easy oral administration route, wide distribution, metabolism mainly in the liver, but not required dosage adjustments due to hepatic impairment, and a single dosage preparation that can increase patient compliance in healing gonorrhea infections. Also, its lower MIC50 than previous antibiotics makes it well-tolerated, therefore making this antibiotic as a potential recommendation for the management of multi-drug resistant gonorrhea in the future. Solithromycin is not inferior to the standard therapy (ceftriaxone and azithromycin), with 80% vs. 84% gonorrhea eradication rates. Per the anatomic site, the eradication rate is 92% in genital, 94% in the pharynx, and 83% in the rectum. However, special attention needs to be paid to the side effects of the gastrointestinal tract of solithromycin, as observed in phase III clinical trials at a dose of 1000 mg in the form of diarrhea (24%) and nausea (21%).
References
ASHA. (2019). Australian STI management guidelines for use in primary care: Gonorrhoea. Australasian Sexual Health Alliance - Www.Ashm.Org.Au. http://www.sti.guidelines.org.au/sexually-transmissible-infections/gonorrhoea/#management
Barrera, C. M., Mykietiuk, A., Metev, H., Nitu, M. F., Karimjee, N., Doreski, P. A., … Oldach, D. (2016). Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: A global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). The Lancet Infectious Diseases, 16(4), 421–430. https://doi.org/10.1016/S1473-3099(16)00017-7
Beauduy, C. E., PharmD, & Winston, L. G. (2018). Chemotherapeutic Drugs. In B. G. Katzung (Ed.), A Lange Medical Book Basic and Clinical Pharmacology (14th ed., pp. 793–916). McGrawHill Education.
Berg, J. M., Tymoczko, J. L., & Stryer, L. (2002). A Ribosome Is a Ribonucleoprotein Particle (70S) Made of a Small (30S) and a Large (50S) Subunit. In Biochemistry (5th ed., p. Section 29.3). W. H. Freeman and Company. https://www.ncbi.nlm.nih.gov/books/NBK22335/
Bignell, C., & Fitzgerald, M. (2011). UK national guideline for the management of gonorrhoea in adults, 2011. International Journal of STD and AIDS, 22(10), 541–547. https://doi.org/10.1258/ijsa.2011.011267
Brown, L. B., Krysiak, R., Kamanga, G., Mapanje, C., Kanyamula, H., Banda, B., … Hoffman, I. F. (2010). Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sexually Transmitted Diseases, 37(3), 169–172. https://doi.org/10.1097/OLQ.0b013e3181bf575c
Carlson-banning, K. M., & Zechiedrich, L. (2013). Antibiotic Classes and Mechanisms of Resistance. Encyclopedia of Metagenomics, 1–13. https://doi.org/10.1007/978-1-4614-6418-1
CDC. (2006). Discontinuation of Spectinomycin. The Morbidity and Mortality Weekly Report and JAMA Journal, 295(19), 2245. https://doi.org/10.1001/jama.295.19.2245
CDC. (2012). Update to CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections. The Morbidity and Mortality Weekly Report (MMWR), 61(31), 590–594. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6131a3.htm
CDC. (2019). The Threat of Antibiotic Resistance: Drug-Resistant Neisseria gonorrhoeae. In Antibiotic Resistance Threats in the United States (pp. 1–118). U.S. Department of Health and Human Services, CDC. https://doi.org/http://dx.doi.org/10.15620/cdc:82532. U.S.
Cempra Inc. (2016). Annual Report Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934: Pharmaceutical Preparations Solithromycin. https://www.sec.gov/Archives/edgar/data/1461993/000156459017002719/cemp-10k_20161231.htm
Cempra Inc., & FDA. (2016a). FDA Briefing Document: Solithromycin Oral Capsule and Injection: Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM527690.pdf
Cempra Inc., & FDA. (2016b). Solithromycin for the Treatment of Community Acquired Pneumonia: Briefing Document for the Antimicrobial Drugs. https://www.fda.gov/media/101134/download
Chen, M. Y., McNulty, A., Avery, A., Whiley, D., Tabrizi, S. N., Hardy, D., … Oldach, D. (2019). Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial. The Lancet Infectious Diseases, 19(8), 833–842. https://doi.org/10.1016/S1473-3099(19)30116-1
Chisholm, S. A., Mouton, J. W., Lewis, D. A., Nichols, T., Ison, C. A., & Livermore, D. M. (2010). Cephalosporin MIC creep among gonococci: Time for a pharmacodynamic rethink? Journal of Antimicrobial Chemotherapy, 65(10), 2141–2148. https://doi.org/10.1093/jac/dkq289
Clarkson, C. W. (2018). Protein Synthesis Inhibitors. Tusom PharmWiki. http://tmedweb.tulane.edu/pharmwiki/doku.php/ribosomal_antibiotics
Cole, M. J., Spiteri, G., Town, K., Unemo, M., Hoffmann, S., Chisholm, S. A., … Eastick, K. (2014). Risk factors for antimicrobial-resistant neisseria gonorrhoeae in Europe. Sexually Transmitted Diseases, 41(12), 723–729. https://doi.org/10.1097/OLQ.0000000000000185
Cole, M. J., Unemo, M., Hoffmann, S., Chisholm, S. A., Ison, C. A., & van de Laar, M. J. (2011). The European gonococcal antimicrobial surveillance programme, 2009. Eurosurveillance, 16(42), 4. https://doi.org/10.2807/ese.16.42.19995-en
Dillon, J.-A., Parti, R., & Thakur, S. (2016). Antibiotic resistance in Neisseria gonorrhoeae: will infections be untreatable in the future? Immunodeficiency, 2(February), 5.
Donald, B. J., Surani, S., Deol, H. S., Mbadugha, U. J., & Udeani, G. (2017). Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: Design, development, and potential place in therapy. Drug Design, Development and Therapy, 11, 3559–3566. https://doi.org/10.2147/DDDT.S119545
Drugs.com. (2020). Tetracycline Dosage Guide with Precautions. Drugs.Com. https://www.drugs.com/dosage/tetracycline.html
Faulkner, R. D., Fernandez, P., Lawrence, G., Sia, L. L., Falkowski, A. J., Weiss, A. I., … Silber, B. M. (1988). Absolute bioavailability of cefixime in man. Journal of Clinical Pharmacology, 28(8), 700–706. https://doi.org/10.1002/j.1552-4604.1988.tb03203.x
Fernandes, P., Martens, E., Bertrand, D., & Pereira, D. (2016). The solithromycin journey—It is all in the chemistry. Bioorganic and Medicinal Chemistry, 24(24), 6420–6428. https://doi.org/10.1016/j.bmc.2016.08.035
File, T. M., Rewerska, B., Vucinić-Mihailović, V., Gonong, J. R. V., Das, A. F., Keedy, K., … Jamieson, B. D. (2016). SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia. Clinical Infectious Diseases, 63(8), 1007–1016. https://doi.org/10.1093/cid/ciw490
Fischbach, M. A., & Walsh, C. T. (2009). Antibiotics for emerging pathogens. Science, 325(5944), 1089–1093. https://doi.org/10.1126/science.1176667
Furuya, R., Onoye, Y., Kanayama, A., Saika, T., Iyoda, T., Tatewaki, M., … Tanaka, M. (2007). Antimicrobial resistance in clinical isolates of Neisseria subflava from the oral cavities of a Japanese population. Journal of Infection and Chemotherapy, 13(5), 302–304. https://doi.org/10.1007/s10156-007-0541-8
Galimand, M., Gerbaud, G., & Courvalin, P. (2000). Spectinomycin resistance in Neisseria spp. due to mutations in 16S rRNA. Antimicrobial Agents and Chemotherapy, 44(5), 1365–1366. https://doi.org/10.1128/AAC.44.5.1365-1366.2000
Golparian, D., Fernandes, P., Ohnishi, M., Jensen, J. S., & Unemo, M. (2012). In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: Potential treatment op. Antimicrobial Agents and Chemotherapy, 56(5), 2739–2742. https://doi.org/10.1128/AAC.00036-12
Hook, E. W., Golden, M., Jamieson, B. D., Dixon, P. B., Harbison, H. S., Lowens, S., & Fernandes, P. (2015). A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated Gonorrhea. Clinical Infectious Diseases, 61(7), 1043–1048. https://doi.org/10.1093/cid/civ478
Ian, C., & Marilyn, R. (2001). Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance. Microbiology and Molecular Biology Reviews, 65(3), 232–260. https://doi.org/10.1128/MMBR.65.2.232
Ison, C. A., Hussey, J., Sankar, K. N., Evans, J., & Alexander, S. (2011). Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Eurosurveillance, 16(14), 1–4. https://doi.org/10.2807/ese.16.14.19833-en
Ito, M., Deguchi, T., Mizutani, K. S., Yasuda, M., Yokoi, S., Ito, S. I., … Ezaki, T. (2005). Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in central Japan. Antimicrobial Agents and Chemotherapy, 49(1), 137–143. https://doi.org/10.1128/AAC.49.1.137-143.2005
Jamieson, B. D., Ciric, S., & Fernandes, P. (2015). Safety and pharmacokinetics of solithromycin in subjects with hepatic impairment. Antimicrobial Agents and Chemotherapy, 59(8), 4379–4386. https://doi.org/10.1128/AAC.04652-14
Judson, F. N., & Rothenberg, R. (1976). Tetracycline in the treatment of uncomplicated male gonorrhea. Journal of the American Venereal Disease Association, 3(2), 56–58.
Kamanga, G., Mhango, C., & Brown, L. B. (2010). Viewpoint: Gentamicin for treatment of gonococcal urethritis in Malawi. Malawi Medical Journal, 22(3), 163–164. https://doi.org/https://doi.org/10.4314/mmj.v22i3.62189
Kemenkes RI. (2015). Pedoman Nasional Penanganan Infeksi Menular Seksual (W. Indriatmi, S. F. Daili, S. N. Tarmizi, & H. D. Prameswari (eds.)). Kementerian Kesehatan Republik Indonesia. https://siha.kemkes.go.id/portal/ims#
Kirkcaldy, R. D., Weston, E., Segurado, A. C., & Hughes, G. (2019). Epidemiology of gonorrhoea: A global perspective. Sexual Health, 16(5), 401–411. https://doi.org/10.1071/SH19061
Lahra, M. (2011). Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian Regions, 2009. Communicable Diseases Intelligence, 35(1), 95–100. https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3501a.htm
Lewis, D. A. (2010). The Gonococcus fights back: Is this time a knock out? Sexually Transmitted Infections, 86(6), 415–421. https://doi.org/10.1136/sti.2010.042648
Llano-Sotelo, B., Dunkle, J., Klepacki, D., Zhang, W., Fernandes, P., Cate, J. H. D., & Mankin, A. S. (2010). Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrobial Agents and Chemotherapy, 54(12), 4961–4970. https://doi.org/10.1128/AAC.00860-10
Lohsen, S., & Stephens, D. S. (2019). Current Macrolide Antibiotics and Their Mechanisms of Action. Antibiotic Drug Resistance, 97–117. https://doi.org/10.1002/9781119282549.ch5
MacDougall, C. (2018). Chemotherapy of Infectious Diseases. In L. L. Brunton, R. Hilal-Dandan, & B. C. Knollmann (Eds.), Goodman and Gilman’s The Pharmacological Basis of Therapeutics (13th ed., pp. 1011–1049). McGrawHill Education.
Mallegol, J., Fernandes, P., Seah, C., Guyard, C., & Melano, R. G. (2013). Determination of in vitro activities of solithromycin at different pHs and its intracellular activity against clinical isolates of Neisseria gonorrhoeae from a laboratory collection. Antimicrobial Agents and Chemotherapy, 57(9), 4322–4328. https://doi.org/10.1128/AAC.00564-13
Marrazzo, J. M., & Apicella, M. A. (2017). Neisseria gonorrhoeae (Gonorrhea). In J. E. Bennett, R. Dolin, & M. J. Blaser (Eds.), Mandell, Douglas, and Bennett’s Infectious Sisease Essentials (p. 305). Elsevier Inc.
Mayo Clinic, & IBM Micromedex. (2020). Tetracycline (Class) (Oral Route, Parenteral Route) Proper Use. Mayoclinic.Org. https://www.mayoclinic.org/drugs-supplements/tetracycline-class-oral-route-parenteral-route/proper-use/drg-20069585
NCBI. (2020a). Solithromycin, CID=25242512. National Library of Medicine National Center for Biotechnology Information - PubChem Database. https://pubchem.ncbi.nlm.nih.gov/compound/Solithromycin
NCBI. (2020b). Telithromycin, CID=3002190. National Library of Medicine National Center for Biotechnology Information - PubChem Database. https://pubchem.ncbi.nlm.nih.gov/compound/Telithromycin#section=2D-Structure
Ndowa, F., & Lusti-Narasimhan, M. (2012). The threat of untreatable gonorrhoea: Implications and consequences for reproductive and sexual morbidity. Reproductive Health Matters, 20(40), 76–82. https://doi.org/10.1016/S0968-8080(12)40653-X
Ng, L. K., Martin, I., Liu, G., & Bryden, L. (2002). Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy, 46(9), 3020–3025. https://doi.org/10.1128/AAC.46.9.3020-3025.2002
Ngeow, Y.-F., Ramachandran, S., & Cheong, Y.-M. (1991). Treatment of gonorrhea with sulbactam/ampicillin. Sexually Transmitted Diseases, 18(3), 192–194. https://doi.org/10.1097/00007435-199107000-00014
Olsen, B., Lan, P. T., Golparian, D., Johansson, E., Khang, T. H., & Unemo, M. (2013). Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011. BMC Infectious Diseases, 13(1). https://doi.org/10.1186/1471-2334-13-40
PERDOSKI. (2017). Panduan Praktik Klinis (PPK) Bagi Dokter Spesialis Kulit dan Kelamin (S. Widaty, H. Soebono, H. Nilasari, M. Y. Listiawan, A. S. Siswati, D. Triwahyudi, C. Rosita, R. Hindritiani, S. W. Yenny, & S. L. Menaldi (eds.)). Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (PERDOSKI). https://www.perdoski.id/uploads/original/2017/10/PPKPERDOSKI2017.pdf
Putnam, S. D., Castanheira, M., Moet, G. J., Farrell, D. J., & Jones, R. N. (2010). CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagnostic Microbiology and Infectious Disease, 66(4), 393–401. https://doi.org/10.1016/j.diagmicrobio.2009.10.013
Putnam, S. D., Sader, H. S., Farrell, D. J., Biedenbach, D. J., & Castanheira, M. (2011). Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: Activity against staphylococci and enterococci. International Journal of Antimicrobial Agents, 37(1), 39–45. https://doi.org/10.1016/j.ijantimicag.2010.08.021
Quillin, S. J., & Seifert, H. S. (2018). Neisseria gonorrhoeae host adaptation and pathogenesis. Nature Reviews Microbiology, 16(4), 226–240. https://doi.org/10.1038/nrmicro.2017.169
Riedel, S., Ross, J. E., Farrell, D. J., Flamm, R. K., & Jones, R. N. (2015). Determination of disk diffusion and MIC quality control guidelines for solithromycin, a novel fluoroketolide antibacterial, against neisseria gonorrhoeae. Journal of Clinical Microbiology, 53(12), 3888–3890. https://doi.org/10.1128/JCM.02250-15
Ropp, P. A., Hu, M., Olesky, M., & Nicholas, R. A. (2002). Mutations in ponA, the gene encoding penicillin-binding protein 1, and a novel locus, penC, are required for high-level chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy, 46(3), 769–777. https://doi.org/10.1128/AAC.46.3.769-777.2002
Rowley, J., Hoorn, S. V., Korenromp, E., Low, N., Unemo, M., Abu-Raddad, L. J., … Taylor, M. M. (2019). Chlamydia, gonorrhoea, trichomoniasis and syphilis: Global prevalence and incidence estimates, 2016. Bulletin of the World Health Organization, 97(8), 548–562. https://doi.org/10.2471/BLT.18.228486
Saika, T., Nishiyama, T., Kanayama, A., Kobayashi, I., Nakayama, H., Tanaka, M., & Naito, S. (2001). Comparison of Neisseria gonorrhoeae isolates from the genital tract and pharynx of two gonorrhea patients. Journal of Infection and Chemotherapy, 7(3), 175–179. https://doi.org/10.1007/s101560100031
Seiple, I. B., Zhang, Z., Jakubec, P., Langlois-Mercier, A., Wright, P. M., Hog, D. T., … Myers, A. G. (2016). A platform for the discovery of new macrolide antibiotics. Nature, 533(7603), 338–345. https://doi.org/10.1038/nature17967
Sergeeva, O. V., Sergiev, P. V., Bogdanov, A. A., & Dontsova, O. A. (2014). Ribosome: Lessons of a molecular factory construction. Molecular Biology, 48(4), 468–484. https://doi.org/10.1134/S0026893314040116
Serio, A. W., Magalhães, M. L., Blanchard, J. S., & Connolly, L. E. (2017). Aminoglycosides: Mechanisms of Action and Resistance. In D. L. Mayers, J. D. Sobel, M. Ouellette, K. S. Kaye, & D. Marchaim (Eds.), Antimicrobial Drug Resistance (2nd ed., pp. 213–229). Springer International Publishing. https://doi.org/https://doi.org/10.1007/978-3-319-46718-4_14
Steingrímsson, O., Olafsson, J. H., Thórarinsson, H., Ryan, R. W., Johnson, R. B., & Tilton, R. C. (1994). Single dose azithromycin treatment of gonorrhea and infections caused by C. trachomatis and U. urealyticum in men. Sexually Transmitted Diseases, 21(1), 43–46. https://doi.org/https://doi.org/10.1097/00007435-199401000-00009
Still, J. G., Schranz, J., Degenhardt, T. P., Scott, D., Fernandes, P., Gutierrez, M. J., & Clark, K. (2011). Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrobial Agents and Chemotherapy, 55(5), 1997–2003. https://doi.org/10.1128/AAC.01429-10
Tenson, T., Lovmar, M., & Ehrenberg, M. (2003). The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. Journal of Molecular Biology, 330(5), 1005–1014. https://doi.org/10.1016/S0022-2836(03)00662-4
Unemo, M., Golparian, D., Nicholas, R., Ohnishi, M., Gallay, A., & Sednaouie, P. (2012). High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: Novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrobial Agents and Chemotherapy, 56(3), 1273–1280. https://doi.org/10.1128/AAC.05760-11
Unemo, M., Golparian, D., Skogen, V., Olsen, A. O., Moi, H., Syversen, G., & Hjelmevoll, S. O. (2013). Neisseria gonorrhoeae strain with high-level resistance to spectinomycin due to a novel resistance mechanism (mutated ribosomal protein S5) Verified in Norway. Antimicrobial Agents and Chemotherapy, 57(2), 1057–1061. https://doi.org/10.1128/AAC.01775-12
Unemo, M., & Nicholas, R. A. (2012). Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiology, 7(12), 1401–1422. https://doi.org/10.2217/fmb.12.117
Unemo, M., & Shafer, W. M. (2014). Antimicrobial resistance in Neisseria gonorrhoeae in the 21st Century: Past, evolution, and future. Clinical Microbiology Reviews, 27(3), 587–613. https://doi.org/10.1128/CMR.00010-14
WHO. (1995). WHO Model Prescribing Information: Drugs used in Bacterial Infections: Sexually transmitted diseases: Gonorrhoeaea. World Health Organization Regional Office for the Eastern Mediterranean. https://apps.who.int/iris/handle/10665/37143
WHO. (2014). Antimicrobial Resistance Global Report on Surveillance. In World Health Organization. https://www.who.int/antimicrobial-resistance/publications/surveillancereport/en/
WHO. (2016). WHO Guidelines for the Treatment of Neisseria gonorrhoeae. WHO Document Production Services. https://www.who.int/reproductivehealth/publications/rtis/gonorrhoea-treatment-guidelines/en/
WHO. (2017). Antibiotic-resistant gonorrhoea on the rise, new drugs needed. World Health Organization News Release. https://www.who.int/news-room/detail/07-07-2017-antibiotic-resistant-gonorrhoea-on-the-rise-new-drugs-needed
Wong, M. L., Chan, R. K. W., & Koh, D. (2002). Promoting condoms for oral sex: Impact on pharyngeal gonorrhea among female brothel-based sex workers. Sexually Transmitted Diseases, 29(6), 311–318. https://doi.org/10.1097/00007435-200206000-00001
Woodhead, J. L., Yang, K., Oldach, D., MacLauchlin, C., Fernandes, P., Watkins, P. B., … Howell, B. A. (2019). Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology Modeling. Pharmaceutical Research, 36(3). https://doi.org/10.1007/s11095-019-2582-y
Workowski, K. A., & Bolan, G. A. (2015). Sexually Transmitted Diseases Treatment Guidelines, 2015. The Morbidity and Mortality Weekly Report (MMWR) Recommendations and Reports, 64(RR-03), 1–137.
Wright, P. M., Seiple, I. B., & Myers, A. G. (2014). The evolving role of chemical synthesis in antibacterial drug discovery. Angewandte Chemie - International Edition, 53(34), 8840–8869. https://doi.org/10.1002/anie.201310843
Barrera, C. M., Mykietiuk, A., Metev, H., Nitu, M. F., Karimjee, N., Doreski, P. A., … Oldach, D. (2016). Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: A global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). The Lancet Infectious Diseases, 16(4), 421–430. https://doi.org/10.1016/S1473-3099(16)00017-7
Beauduy, C. E., PharmD, & Winston, L. G. (2018). Chemotherapeutic Drugs. In B. G. Katzung (Ed.), A Lange Medical Book Basic and Clinical Pharmacology (14th ed., pp. 793–916). McGrawHill Education.
Berg, J. M., Tymoczko, J. L., & Stryer, L. (2002). A Ribosome Is a Ribonucleoprotein Particle (70S) Made of a Small (30S) and a Large (50S) Subunit. In Biochemistry (5th ed., p. Section 29.3). W. H. Freeman and Company. https://www.ncbi.nlm.nih.gov/books/NBK22335/
Bignell, C., & Fitzgerald, M. (2011). UK national guideline for the management of gonorrhoea in adults, 2011. International Journal of STD and AIDS, 22(10), 541–547. https://doi.org/10.1258/ijsa.2011.011267
Brown, L. B., Krysiak, R., Kamanga, G., Mapanje, C., Kanyamula, H., Banda, B., … Hoffman, I. F. (2010). Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sexually Transmitted Diseases, 37(3), 169–172. https://doi.org/10.1097/OLQ.0b013e3181bf575c
Carlson-banning, K. M., & Zechiedrich, L. (2013). Antibiotic Classes and Mechanisms of Resistance. Encyclopedia of Metagenomics, 1–13. https://doi.org/10.1007/978-1-4614-6418-1
CDC. (2006). Discontinuation of Spectinomycin. The Morbidity and Mortality Weekly Report and JAMA Journal, 295(19), 2245. https://doi.org/10.1001/jama.295.19.2245
CDC. (2012). Update to CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections. The Morbidity and Mortality Weekly Report (MMWR), 61(31), 590–594. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6131a3.htm
CDC. (2019). The Threat of Antibiotic Resistance: Drug-Resistant Neisseria gonorrhoeae. In Antibiotic Resistance Threats in the United States (pp. 1–118). U.S. Department of Health and Human Services, CDC. https://doi.org/http://dx.doi.org/10.15620/cdc:82532. U.S.
Cempra Inc. (2016). Annual Report Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934: Pharmaceutical Preparations Solithromycin. https://www.sec.gov/Archives/edgar/data/1461993/000156459017002719/cemp-10k_20161231.htm
Cempra Inc., & FDA. (2016a). FDA Briefing Document: Solithromycin Oral Capsule and Injection: Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM527690.pdf
Cempra Inc., & FDA. (2016b). Solithromycin for the Treatment of Community Acquired Pneumonia: Briefing Document for the Antimicrobial Drugs. https://www.fda.gov/media/101134/download
Chen, M. Y., McNulty, A., Avery, A., Whiley, D., Tabrizi, S. N., Hardy, D., … Oldach, D. (2019). Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial. The Lancet Infectious Diseases, 19(8), 833–842. https://doi.org/10.1016/S1473-3099(19)30116-1
Chisholm, S. A., Mouton, J. W., Lewis, D. A., Nichols, T., Ison, C. A., & Livermore, D. M. (2010). Cephalosporin MIC creep among gonococci: Time for a pharmacodynamic rethink? Journal of Antimicrobial Chemotherapy, 65(10), 2141–2148. https://doi.org/10.1093/jac/dkq289
Clarkson, C. W. (2018). Protein Synthesis Inhibitors. Tusom PharmWiki. http://tmedweb.tulane.edu/pharmwiki/doku.php/ribosomal_antibiotics
Cole, M. J., Spiteri, G., Town, K., Unemo, M., Hoffmann, S., Chisholm, S. A., … Eastick, K. (2014). Risk factors for antimicrobial-resistant neisseria gonorrhoeae in Europe. Sexually Transmitted Diseases, 41(12), 723–729. https://doi.org/10.1097/OLQ.0000000000000185
Cole, M. J., Unemo, M., Hoffmann, S., Chisholm, S. A., Ison, C. A., & van de Laar, M. J. (2011). The European gonococcal antimicrobial surveillance programme, 2009. Eurosurveillance, 16(42), 4. https://doi.org/10.2807/ese.16.42.19995-en
Dillon, J.-A., Parti, R., & Thakur, S. (2016). Antibiotic resistance in Neisseria gonorrhoeae: will infections be untreatable in the future? Immunodeficiency, 2(February), 5.
Donald, B. J., Surani, S., Deol, H. S., Mbadugha, U. J., & Udeani, G. (2017). Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: Design, development, and potential place in therapy. Drug Design, Development and Therapy, 11, 3559–3566. https://doi.org/10.2147/DDDT.S119545
Drugs.com. (2020). Tetracycline Dosage Guide with Precautions. Drugs.Com. https://www.drugs.com/dosage/tetracycline.html
Faulkner, R. D., Fernandez, P., Lawrence, G., Sia, L. L., Falkowski, A. J., Weiss, A. I., … Silber, B. M. (1988). Absolute bioavailability of cefixime in man. Journal of Clinical Pharmacology, 28(8), 700–706. https://doi.org/10.1002/j.1552-4604.1988.tb03203.x
Fernandes, P., Martens, E., Bertrand, D., & Pereira, D. (2016). The solithromycin journey—It is all in the chemistry. Bioorganic and Medicinal Chemistry, 24(24), 6420–6428. https://doi.org/10.1016/j.bmc.2016.08.035
File, T. M., Rewerska, B., Vucinić-Mihailović, V., Gonong, J. R. V., Das, A. F., Keedy, K., … Jamieson, B. D. (2016). SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia. Clinical Infectious Diseases, 63(8), 1007–1016. https://doi.org/10.1093/cid/ciw490
Fischbach, M. A., & Walsh, C. T. (2009). Antibiotics for emerging pathogens. Science, 325(5944), 1089–1093. https://doi.org/10.1126/science.1176667
Furuya, R., Onoye, Y., Kanayama, A., Saika, T., Iyoda, T., Tatewaki, M., … Tanaka, M. (2007). Antimicrobial resistance in clinical isolates of Neisseria subflava from the oral cavities of a Japanese population. Journal of Infection and Chemotherapy, 13(5), 302–304. https://doi.org/10.1007/s10156-007-0541-8
Galimand, M., Gerbaud, G., & Courvalin, P. (2000). Spectinomycin resistance in Neisseria spp. due to mutations in 16S rRNA. Antimicrobial Agents and Chemotherapy, 44(5), 1365–1366. https://doi.org/10.1128/AAC.44.5.1365-1366.2000
Golparian, D., Fernandes, P., Ohnishi, M., Jensen, J. S., & Unemo, M. (2012). In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: Potential treatment op. Antimicrobial Agents and Chemotherapy, 56(5), 2739–2742. https://doi.org/10.1128/AAC.00036-12
Hook, E. W., Golden, M., Jamieson, B. D., Dixon, P. B., Harbison, H. S., Lowens, S., & Fernandes, P. (2015). A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated Gonorrhea. Clinical Infectious Diseases, 61(7), 1043–1048. https://doi.org/10.1093/cid/civ478
Ian, C., & Marilyn, R. (2001). Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance. Microbiology and Molecular Biology Reviews, 65(3), 232–260. https://doi.org/10.1128/MMBR.65.2.232
Ison, C. A., Hussey, J., Sankar, K. N., Evans, J., & Alexander, S. (2011). Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Eurosurveillance, 16(14), 1–4. https://doi.org/10.2807/ese.16.14.19833-en
Ito, M., Deguchi, T., Mizutani, K. S., Yasuda, M., Yokoi, S., Ito, S. I., … Ezaki, T. (2005). Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in central Japan. Antimicrobial Agents and Chemotherapy, 49(1), 137–143. https://doi.org/10.1128/AAC.49.1.137-143.2005
Jamieson, B. D., Ciric, S., & Fernandes, P. (2015). Safety and pharmacokinetics of solithromycin in subjects with hepatic impairment. Antimicrobial Agents and Chemotherapy, 59(8), 4379–4386. https://doi.org/10.1128/AAC.04652-14
Judson, F. N., & Rothenberg, R. (1976). Tetracycline in the treatment of uncomplicated male gonorrhea. Journal of the American Venereal Disease Association, 3(2), 56–58.
Kamanga, G., Mhango, C., & Brown, L. B. (2010). Viewpoint: Gentamicin for treatment of gonococcal urethritis in Malawi. Malawi Medical Journal, 22(3), 163–164. https://doi.org/https://doi.org/10.4314/mmj.v22i3.62189
Kemenkes RI. (2015). Pedoman Nasional Penanganan Infeksi Menular Seksual (W. Indriatmi, S. F. Daili, S. N. Tarmizi, & H. D. Prameswari (eds.)). Kementerian Kesehatan Republik Indonesia. https://siha.kemkes.go.id/portal/ims#
Kirkcaldy, R. D., Weston, E., Segurado, A. C., & Hughes, G. (2019). Epidemiology of gonorrhoea: A global perspective. Sexual Health, 16(5), 401–411. https://doi.org/10.1071/SH19061
Lahra, M. (2011). Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian Regions, 2009. Communicable Diseases Intelligence, 35(1), 95–100. https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3501a.htm
Lewis, D. A. (2010). The Gonococcus fights back: Is this time a knock out? Sexually Transmitted Infections, 86(6), 415–421. https://doi.org/10.1136/sti.2010.042648
Llano-Sotelo, B., Dunkle, J., Klepacki, D., Zhang, W., Fernandes, P., Cate, J. H. D., & Mankin, A. S. (2010). Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrobial Agents and Chemotherapy, 54(12), 4961–4970. https://doi.org/10.1128/AAC.00860-10
Lohsen, S., & Stephens, D. S. (2019). Current Macrolide Antibiotics and Their Mechanisms of Action. Antibiotic Drug Resistance, 97–117. https://doi.org/10.1002/9781119282549.ch5
MacDougall, C. (2018). Chemotherapy of Infectious Diseases. In L. L. Brunton, R. Hilal-Dandan, & B. C. Knollmann (Eds.), Goodman and Gilman’s The Pharmacological Basis of Therapeutics (13th ed., pp. 1011–1049). McGrawHill Education.
Mallegol, J., Fernandes, P., Seah, C., Guyard, C., & Melano, R. G. (2013). Determination of in vitro activities of solithromycin at different pHs and its intracellular activity against clinical isolates of Neisseria gonorrhoeae from a laboratory collection. Antimicrobial Agents and Chemotherapy, 57(9), 4322–4328. https://doi.org/10.1128/AAC.00564-13
Marrazzo, J. M., & Apicella, M. A. (2017). Neisseria gonorrhoeae (Gonorrhea). In J. E. Bennett, R. Dolin, & M. J. Blaser (Eds.), Mandell, Douglas, and Bennett’s Infectious Sisease Essentials (p. 305). Elsevier Inc.
Mayo Clinic, & IBM Micromedex. (2020). Tetracycline (Class) (Oral Route, Parenteral Route) Proper Use. Mayoclinic.Org. https://www.mayoclinic.org/drugs-supplements/tetracycline-class-oral-route-parenteral-route/proper-use/drg-20069585
NCBI. (2020a). Solithromycin, CID=25242512. National Library of Medicine National Center for Biotechnology Information - PubChem Database. https://pubchem.ncbi.nlm.nih.gov/compound/Solithromycin
NCBI. (2020b). Telithromycin, CID=3002190. National Library of Medicine National Center for Biotechnology Information - PubChem Database. https://pubchem.ncbi.nlm.nih.gov/compound/Telithromycin#section=2D-Structure
Ndowa, F., & Lusti-Narasimhan, M. (2012). The threat of untreatable gonorrhoea: Implications and consequences for reproductive and sexual morbidity. Reproductive Health Matters, 20(40), 76–82. https://doi.org/10.1016/S0968-8080(12)40653-X
Ng, L. K., Martin, I., Liu, G., & Bryden, L. (2002). Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy, 46(9), 3020–3025. https://doi.org/10.1128/AAC.46.9.3020-3025.2002
Ngeow, Y.-F., Ramachandran, S., & Cheong, Y.-M. (1991). Treatment of gonorrhea with sulbactam/ampicillin. Sexually Transmitted Diseases, 18(3), 192–194. https://doi.org/10.1097/00007435-199107000-00014
Olsen, B., Lan, P. T., Golparian, D., Johansson, E., Khang, T. H., & Unemo, M. (2013). Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011. BMC Infectious Diseases, 13(1). https://doi.org/10.1186/1471-2334-13-40
PERDOSKI. (2017). Panduan Praktik Klinis (PPK) Bagi Dokter Spesialis Kulit dan Kelamin (S. Widaty, H. Soebono, H. Nilasari, M. Y. Listiawan, A. S. Siswati, D. Triwahyudi, C. Rosita, R. Hindritiani, S. W. Yenny, & S. L. Menaldi (eds.)). Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (PERDOSKI). https://www.perdoski.id/uploads/original/2017/10/PPKPERDOSKI2017.pdf
Putnam, S. D., Castanheira, M., Moet, G. J., Farrell, D. J., & Jones, R. N. (2010). CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagnostic Microbiology and Infectious Disease, 66(4), 393–401. https://doi.org/10.1016/j.diagmicrobio.2009.10.013
Putnam, S. D., Sader, H. S., Farrell, D. J., Biedenbach, D. J., & Castanheira, M. (2011). Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: Activity against staphylococci and enterococci. International Journal of Antimicrobial Agents, 37(1), 39–45. https://doi.org/10.1016/j.ijantimicag.2010.08.021
Quillin, S. J., & Seifert, H. S. (2018). Neisseria gonorrhoeae host adaptation and pathogenesis. Nature Reviews Microbiology, 16(4), 226–240. https://doi.org/10.1038/nrmicro.2017.169
Riedel, S., Ross, J. E., Farrell, D. J., Flamm, R. K., & Jones, R. N. (2015). Determination of disk diffusion and MIC quality control guidelines for solithromycin, a novel fluoroketolide antibacterial, against neisseria gonorrhoeae. Journal of Clinical Microbiology, 53(12), 3888–3890. https://doi.org/10.1128/JCM.02250-15
Ropp, P. A., Hu, M., Olesky, M., & Nicholas, R. A. (2002). Mutations in ponA, the gene encoding penicillin-binding protein 1, and a novel locus, penC, are required for high-level chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy, 46(3), 769–777. https://doi.org/10.1128/AAC.46.3.769-777.2002
Rowley, J., Hoorn, S. V., Korenromp, E., Low, N., Unemo, M., Abu-Raddad, L. J., … Taylor, M. M. (2019). Chlamydia, gonorrhoea, trichomoniasis and syphilis: Global prevalence and incidence estimates, 2016. Bulletin of the World Health Organization, 97(8), 548–562. https://doi.org/10.2471/BLT.18.228486
Saika, T., Nishiyama, T., Kanayama, A., Kobayashi, I., Nakayama, H., Tanaka, M., & Naito, S. (2001). Comparison of Neisseria gonorrhoeae isolates from the genital tract and pharynx of two gonorrhea patients. Journal of Infection and Chemotherapy, 7(3), 175–179. https://doi.org/10.1007/s101560100031
Seiple, I. B., Zhang, Z., Jakubec, P., Langlois-Mercier, A., Wright, P. M., Hog, D. T., … Myers, A. G. (2016). A platform for the discovery of new macrolide antibiotics. Nature, 533(7603), 338–345. https://doi.org/10.1038/nature17967
Sergeeva, O. V., Sergiev, P. V., Bogdanov, A. A., & Dontsova, O. A. (2014). Ribosome: Lessons of a molecular factory construction. Molecular Biology, 48(4), 468–484. https://doi.org/10.1134/S0026893314040116
Serio, A. W., Magalhães, M. L., Blanchard, J. S., & Connolly, L. E. (2017). Aminoglycosides: Mechanisms of Action and Resistance. In D. L. Mayers, J. D. Sobel, M. Ouellette, K. S. Kaye, & D. Marchaim (Eds.), Antimicrobial Drug Resistance (2nd ed., pp. 213–229). Springer International Publishing. https://doi.org/https://doi.org/10.1007/978-3-319-46718-4_14
Steingrímsson, O., Olafsson, J. H., Thórarinsson, H., Ryan, R. W., Johnson, R. B., & Tilton, R. C. (1994). Single dose azithromycin treatment of gonorrhea and infections caused by C. trachomatis and U. urealyticum in men. Sexually Transmitted Diseases, 21(1), 43–46. https://doi.org/https://doi.org/10.1097/00007435-199401000-00009
Still, J. G., Schranz, J., Degenhardt, T. P., Scott, D., Fernandes, P., Gutierrez, M. J., & Clark, K. (2011). Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrobial Agents and Chemotherapy, 55(5), 1997–2003. https://doi.org/10.1128/AAC.01429-10
Tenson, T., Lovmar, M., & Ehrenberg, M. (2003). The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. Journal of Molecular Biology, 330(5), 1005–1014. https://doi.org/10.1016/S0022-2836(03)00662-4
Unemo, M., Golparian, D., Nicholas, R., Ohnishi, M., Gallay, A., & Sednaouie, P. (2012). High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: Novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrobial Agents and Chemotherapy, 56(3), 1273–1280. https://doi.org/10.1128/AAC.05760-11
Unemo, M., Golparian, D., Skogen, V., Olsen, A. O., Moi, H., Syversen, G., & Hjelmevoll, S. O. (2013). Neisseria gonorrhoeae strain with high-level resistance to spectinomycin due to a novel resistance mechanism (mutated ribosomal protein S5) Verified in Norway. Antimicrobial Agents and Chemotherapy, 57(2), 1057–1061. https://doi.org/10.1128/AAC.01775-12
Unemo, M., & Nicholas, R. A. (2012). Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiology, 7(12), 1401–1422. https://doi.org/10.2217/fmb.12.117
Unemo, M., & Shafer, W. M. (2014). Antimicrobial resistance in Neisseria gonorrhoeae in the 21st Century: Past, evolution, and future. Clinical Microbiology Reviews, 27(3), 587–613. https://doi.org/10.1128/CMR.00010-14
WHO. (1995). WHO Model Prescribing Information: Drugs used in Bacterial Infections: Sexually transmitted diseases: Gonorrhoeaea. World Health Organization Regional Office for the Eastern Mediterranean. https://apps.who.int/iris/handle/10665/37143
WHO. (2014). Antimicrobial Resistance Global Report on Surveillance. In World Health Organization. https://www.who.int/antimicrobial-resistance/publications/surveillancereport/en/
WHO. (2016). WHO Guidelines for the Treatment of Neisseria gonorrhoeae. WHO Document Production Services. https://www.who.int/reproductivehealth/publications/rtis/gonorrhoea-treatment-guidelines/en/
WHO. (2017). Antibiotic-resistant gonorrhoea on the rise, new drugs needed. World Health Organization News Release. https://www.who.int/news-room/detail/07-07-2017-antibiotic-resistant-gonorrhoea-on-the-rise-new-drugs-needed
Wong, M. L., Chan, R. K. W., & Koh, D. (2002). Promoting condoms for oral sex: Impact on pharyngeal gonorrhea among female brothel-based sex workers. Sexually Transmitted Diseases, 29(6), 311–318. https://doi.org/10.1097/00007435-200206000-00001
Woodhead, J. L., Yang, K., Oldach, D., MacLauchlin, C., Fernandes, P., Watkins, P. B., … Howell, B. A. (2019). Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology Modeling. Pharmaceutical Research, 36(3). https://doi.org/10.1007/s11095-019-2582-y
Workowski, K. A., & Bolan, G. A. (2015). Sexually Transmitted Diseases Treatment Guidelines, 2015. The Morbidity and Mortality Weekly Report (MMWR) Recommendations and Reports, 64(RR-03), 1–137.
Wright, P. M., Seiple, I. B., & Myers, A. G. (2014). The evolving role of chemical synthesis in antibacterial drug discovery. Angewandte Chemie - International Edition, 53(34), 8840–8869. https://doi.org/10.1002/anie.201310843
Published
2020-12-28
How to Cite
Habiburrahman, M., Soetikno, V., Sirait, W. R., & Savira, M. (2020). Solithromycin as A Potential Novel Antibiotic Against Neisseria Gonorrhoeae Resistance. Indonesian Journal of Pharmacy, 31(4), 335–353. https://doi.org/10.22146/ijp.1123
Issue
Section
Research Article
Copyright (c) 2020 Indonesian Journal of Pharmacy
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
